Market News

Piramal Pharma Share Price Gains Over 3% As US FDA Closes Inspection

With the closing of the inspection, strong buying interest has been witnessed in Piramal Pharma stock

Stock Alert: JSW Infra, Ideaforge Tech, Uno Minda, Orchid Pharma

Ideaforge Technology launced the qualified institutional placement (QIP) issue and fixed the floor price at Rs 835.86 per share. The company may offer a discount of up to 5% to the floor price.

Saraswati Commercial (India) Ltd leads gainers in 'B' group

DB (International) Stock Brokers Ltd, IOL Chemicals & Pharmaceuticals Ltd, Kaushalya Infrastructure Development Corpn Ltd and Kothari Industrial Corporation Ltd are among the other gainers in the BSE's 'B' group today, 07 July 2026.

Sun Pharma Share Price Live Updates: Sun Pharma's Stock Shows Weekly Growth

Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve

Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The company is investing ₹3,000 crore in expanding capacities, particularly for high-value CDMO services, which are projected to double their revenue share by 2030. Analysts are optimistic, raising earnings forecasts and maintaining a 'BUY' rating, anticipating continued growth across its diverse segments.

Cipla Share Price Live Updates: Cipla's Stock Price Movement

Sun Pharma Share Price Live Updates: Sun Pharma's Stock Shows Positive Momentum

Cipla Share Price Live Updates: Cipla's Stock Breaks Through Resistance Levels

Cipla Share Price Gains 4% As Citi Maintains Bullish Stance For 90-Day Momentum: Check Target Price

Cipla share price gained 4% as Citi held a bullish stance on the stock.

Cipla Share Price: Citi highlights multiple triggers for 90-day positive catalyst watch

Citi believes a series of near-term triggers in the US market could support further upside for the stock. These include the potential approval of generic Flovent (gFlovent), the launch of generic Ventolin (gVentolin), and Cipla's growing presence in the Nintedanib market, where its market share is approaching 50%.

SEBI brings back stock market route for company share buybacks from August 2026

Companies will once again be able to buy back their shares directly from the stock market after SEBI approved the reintroduction of the open-market buyback mechanism. The revised framework will take effect from August 1, 2026, with buybacks allowed over a maximum period of 60 days.

Small-cap pharma stock hits 52-week high after fundraising move. Details here

Sudarshan Pharma share price has gained over 21% in one month and has jumped 56% in three months. The smallcap stock has rallied 47% in six months, and has advanced 24% in one year. Sudarshan Pharma shares have delivered multibagger returns of 400%.